Merck to Collaborate With Exelixis on Phase 3 Colorectal Cancer Trial

MT Newswires Live05-19 20:50

Merck (MRK) has signed an agreement with Exelixis (EXEL) to supply it with the Keytruda QLEX injection for a phase 3 trial in patients with resected stage 2/3 colorectal cancer, Exelixis said Tuesday.

The trial will evaluate Exelixis' zanzalintinib oral kinase inhibitor in combination with and without Keytruda QLEX in patients who, following definitive therapy, have tested positive for molecular residual disease and have no radiographic evidence of disease, Exelixis said.

The primary endpoint of the trial will be disease-free survival, with key secondary endpoints including circulating tumor DNA clearance, the company said.

Exelixis added that the trial is expected to commence in mid-2026.

Exelixis shares were up 1.4% in Tuesday's premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment